Notice of Closed Meeting, 60210-60211 [2023-18806]
Download as PDF
60210
Federal Register / Vol. 88, No. 168 / Thursday, August 31, 2023 / Notices
other forms of information technology.
OMB has approved this information
collection for use through February 29,
2024. DoD, GSA, and NASA propose
that OMB extend its approval for use for
three additional years beyond the
current expiration date.
DATES: DoD, GSA, and NASA will
consider all comments received by
October 30, 2023.
ADDRESSES: DoD, GSA, and NASA
invite interested persons to submit
comments on this collection through
https://www.regulations.gov and follow
the instructions on the site. This website
provides the ability to type short
comments directly into the comment
field or attach a file for lengthier
comments. If there are difficulties
submitting comments, contact the GSA
Regulatory Secretariat Division at 202–
501–4755 or GSARegSec@gsa.gov.
Instructions: All items submitted
must cite OMB Control No. 9000–0157,
Architect-Engineer Qualifications (SF–
330). Comments received generally will
be posted without change to https://
www.regulations.gov, including any
personal and/or business confidential
information provided. To confirm
receipt of your comment(s), please
check www.regulations.gov,
approximately two-to-three days after
submission to verify posting.
FOR FURTHER INFORMATION CONTACT:
Zenaida Delgado, Procurement Analyst,
at telephone 202–969–7207, or
zenaida.delgado@gsa.gov.
SUPPLEMENTARY INFORMATION:
A. OMB Control Number, Title, and
Any Associated Form(s)
9000–0157, Architect-Engineer
Qualifications, SF–330.
ddrumheller on DSK120RN23PROD with NOTICES1
B. Need and Uses
This clearance covers the information
that offerors must submit to comply
with the following Federal Acquisition
Regulation (FAR) requirement:
Standard Form (SF) 330, ArchitectEngineer Qualifications. As specified in
FAR 36.702(b), an architect-engineer
firm must provide information about its
qualifications for a specific contract
when the contract amount is expected to
exceed the simplified acquisition
threshold (SAT).
Part I—Contract-Specific
Qualifications. The information on the
form is reviewed by a selection panel
composed of professionals and assists
the panel in selecting the most qualified
architect-engineer firm to perform the
specific project. The form is designed to
provide a uniform method for architectengineer firms to submit information on
experience, personnel, and capabilities
VerDate Sep<11>2014
18:04 Aug 30, 2023
Jkt 259001
of the architect-engineer firm to perform
along with information on the
consultants they expect to collaborate
with on the specific project. Part I of the
SF 330 may be used when the contract
amount is expected to be at or below the
SAT, if the contracting officer
determines that its use is appropriate.
Part II—General Qualifications. The
information obtained on this form is
used to determine if a firm should be
solicited for architect-engineer projects.
Architect-engineer firms are encouraged
to update the form annually. Part II of
the SF 330 is used to obtain information
from an architect-engineer firm about its
general professional qualifications.
The SF 330 accomplishes the
following:
• Expands essential information
about qualifications and experience data
including:
❖ An organizational chart of all
participating firms and key personnel.
❖ For all key personnel, a description
of their experience in 5 relevant
projects.
❖ A description of each example
project performed by the project team
(or some elements of the project team)
and its relevance to the agency’s
proposed contract.
❖ A matrix of key personnel who
participated in the example projects.
This matrix graphically illustrates the
degree to which the proposed key
personnel have worked together before
on similar projects.
• Reflects current architect-engineer
disciplines, experience types and
technology.
• Permits limited submission length
thereby reducing costs for both the
architect-engineer industry and the
Government. Lengthy submissions do
not necessarily lead to a better decision
on the best-qualified firm. The proposed
SF 330 indicates that agencies may limit
the length of a firm’s submissions, either
certain sections or the entire package.
The Government’s right to impose such
limitations was established in case law
(Coffman Specialties, Inc., B–284546.
N–284546/2, 2000 U.S. Comp. Gen.
LEXIS 58, May 10, 2000).
The contracting officer uses the
information provided on the SF 330 to
evaluate firms to select an architectengineer firm for a contract.
C. Annual Burden
Respondents: 682.
Total Annual Responses: 2,728.
Total Burden Hours: 79,112.
Obtaining Copies: Requesters may
obtain a copy of the information
collection documents from the GSA
Regulatory Secretariat Division by
calling 202–501–4755 or emailing
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
GSARegSec@gsa.gov. Please cite OMB
Control No. 9000–0157, ArchitectEngineer Qualifications (SF–330).
Janet Fry,
Director, Federal Acquisition Policy Division,
Office of Governmentwide Acquisition Policy,
Office of Acquisition Policy, Office of
Governmentwide Policy.
[FR Doc. 2023–18843 Filed 8–30–23; 8:45 am]
BILLING CODE 6820–EP–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Pursuant to section 5 U.S.C. 1009(d),
notice is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, CDC, pursuant to Public Law
92–463. The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel; (SEP)–
RFA–OH–22–003, Occupational Safety
and Health Training Project Grants.
Date: November 30, 2023.
Time: 1 p.m.–5 p.m., EST.
Place: Video-Assisted Meeting.
Agenda: To review and evaluate grant
applications.
FOR FURTHER INFORMATION CONTACT:
Marilyn Ridenour, B.S.N., M.P.H.,
Scientific Review Official, Office of
Extramural Programs, Centers for
Disease Control and Prevention, 1095
Willowdale Road, Morgantown, West
Virginia 26505. Telephone: (304) 285–
5879; Email: MRidenour@cdc.gov.
The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
E:\FR\FM\31AUN1.SGM
31AUN1
Federal Register / Vol. 88, No. 168 / Thursday, August 31, 2023 / Notices
20852, 301–796–3794, PRAStaff@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business
Initiatives, Office of the Chief Operating
Officer, Centers for Disease Control and
Prevention.
[FR Doc. 2023–18806 Filed 8–30–23; 8:45 am]
Rapid Response Surveys
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2023–N–0940]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Food and Drug
Administration Rapid Response
Surveys
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Submit written comments
(including recommendations) on the
collection of information by October 2,
2023.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be submitted to https://
www.reginfo.gov/public/do/PRAMain.
Find this particular information
collection by selecting ‘‘Currently under
Review—Open for Public Comments’’ or
by using the search function. The OMB
control number for this information
collection is 0910–0500. Also include
the FDA docket number found in
brackets in the heading of this
document.
SUMMARY:
ddrumheller on DSK120RN23PROD with NOTICES1
FOR FURTHER INFORMATION CONTACT:
JonnaLynn Capezzuto, Office of
Operations, Food and Drug
Administration, Three White Flint
North, 10 a.m.–12 p.m., 11601
Landsdown St., North Bethesda, MD
VerDate Sep<11>2014
18:04 Aug 30, 2023
Jkt 259001
OMB Control Number 0910–0500—
Extension
This generic information collection
supports research conducted by FDA, as
authorized under section 1003(d)(2) of
the Federal Food, Drug, and Cosmetic
Act (21 U.S.C. 393(d)(2)).
FDA is requesting extension of OMB
approval to conduct rapid response
surveys (RRS). Through these surveys,
FDA seeks to determine whether a
problem impacts the public health and
to quickly obtain vital information about
risks and interventions. FDA will use
the information gathered from these
surveys to make quick turnaround
decisions about safety problems or risk
management solutions so the Agency
may take appropriate public health
action including dissemination of
information as necessary. Participation
in these surveys is voluntary.
Respondents may include
manufacturers and distributors of
biologics, drugs, food, animal food and
drugs, dietary supplements, food
additives, cosmetics, medical devices,
and tobacco products; distributors;
sponsors and importers; consumers;
healthcare professionals; hospitals;
specialized medical facilities (e.g.,
cardiac surgery, obstetrics/gynecology
services, pediatric services, etc.) and
other user facilities including nursing
homes, ambulatory surgical and
outpatient diagnostic and treatment
facilities when FDA must quickly
determine whether or not a problem
impacts the public health. Once FDA
understands the need for additional
surveillance data to address a potential
public health hazard, the appropriate
respondents will be identified for each
unique RRS.
In the Federal Register of April 20,
2023 (88 FR 24423), FDA published a
60-day notice requesting public
comment on the proposed collection of
information. We received one comment,
which was generally supportive of
FDA’s use of RRS. (Comment) The
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
60211
comment suggested that FDA
‘‘authorize, develop, and implement a
mechanism that provides States and the
most local level of public health
departments immediate notification and
access to RRS results when the FDA
issues a RRS wholly or partially in their
areas of jurisdiction.’’ (Response) FDA
already has in place mechanisms to
share pertinent health information with
State, local, and tribal authorities. We
currently share aggregated data (without
personally identifiable information) of
hospital reporting RRS. However, FDA’s
use of RRS has not recently developed
data about potential safety problems or
risk management solutions that would
require development of a new
mechanism for immediate notification
and access to RRS results. For example,
FDA used a RRS to identify and
maintain a list of drugs essential for the
care and management of hospitalized
patients with COVID–19, particularly
for ventilated patients in the intensive
care units. FDA used the information to
help to identify drugs that may be at risk
of a regional or national shortage, and to
help ensure these drugs remain
available to meet the needs of our
nation. FDA also used a RRS to engage
stakeholders when developing the food
safety surveillance sampling
assignments. FDA shared information
with key external stakeholders on the
hot pepper and cucumber sampling
assignments and garnered industry
feedback through survey questions to
ensure that sample collection is done as
effectively and efficiently as possible.
Neither of these surveys developed
information that would require
development of a new mechanism for
immediate notification and access to
RRS results. The latest update survey
data from FDA can be found here:
https://www.fda.gov/science-research/
fda-science-forum/fda-covid-19-criticalcare-drug-monitoring-survey-portalongoing-surveillance-critical-drugsrelated. Please also note that if you or
your hospital stakeholders are
experiencing a drug shortage and need
assistance on how to obtain supply,
please refer to the information at
Drugshortages@fda.hhs.gov. FDA Drug
Shortage Staff responds to all reports
received on a daily basis.
FDA estimates the burden of this
collection of information as follows:
E:\FR\FM\31AUN1.SGM
31AUN1
Agencies
[Federal Register Volume 88, Number 168 (Thursday, August 31, 2023)]
[Notices]
[Pages 60210-60211]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-18806]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 5 U.S.C. 1009(d), notice is hereby given of the
following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Office of
Strategic Business Initiatives, Office of the Chief Operating Officer,
CDC, pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel; (SEP)-RFA-OH-22-003, Occupational
Safety and Health Training Project Grants.
Date: November 30, 2023.
Time: 1 p.m.-5 p.m., EST.
Place: Video-Assisted Meeting.
Agenda: To review and evaluate grant applications.
FOR FURTHER INFORMATION CONTACT: Marilyn Ridenour, B.S.N., M.P.H.,
Scientific Review Official, Office of Extramural Programs, Centers for
Disease Control and Prevention, 1095 Willowdale Road, Morgantown, West
Virginia 26505. Telephone: (304) 285-5879; Email: [email protected].
The Director, Office of Strategic Business Initiatives, Office of
the Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
[[Page 60211]]
Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Office of Strategic Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-18806 Filed 8-30-23; 8:45 am]
BILLING CODE 4163-18-P